Avelumab and Merkel Cell Carcinoma: Evaluating the Medical Literature on Associated Risk

From General Health Education to Specific Exposure Concerns

The legacy of general health and science information has long served as a foundation for public understanding of medical risks, emphasizing broad awareness of disease prevention and treatment options. Within this framework, discussions of cancer have historically focused on lifestyle factors, environmental exposures, and therapeutic interventions, with an underlying assumption that medical treatments are designed to reduce harm. However, as pharmaceutical science advances, the scope of inquiry must expand to include the nuanced relationship between therapeutic agents and unintended outcomes. In the context of mass production and widespread clinical adoption, the transition from general health education to specific occupational exposure concern becomes necessary. This pivot requires examining how a drug like avelumab, an immune checkpoint inhibitor, may be associated with the development of Merkel cell carcinoma—a rare but aggressive skin cancer. While the legacy context provides a baseline for understanding cancer risk factors, the shift toward occupational exposure demands a focused analysis of how healthcare workers, patients, and manufacturing personnel might encounter avelumab in ways that could influence carcinogenic processes. This transition does not presuppose causation but rather establishes a framework for investigating potential links between exposure and disease, moving from abstract health principles to concrete risk assessment in production and clinical environments.

Bridging to Avelumab and Merkel Cell Carcinoma

Building on the general framework of health risk assessment, we now turn to the specific case of avelumab and its relationship with Merkel cell carcinoma (MCC). Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the JAVELIN Merkel 200 trial, a two-part, single-arm phase II study in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is the first therapeutic agent specifically approved for this indication and is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Understanding Merkel Cell Carcinoma and Its Risk Factors

Merkel cell carcinoma is a rare but highly aggressive skin cancer with neuroendocrine differentiation, associated with chronic ultraviolet light exposure and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing, and it is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). In the context of avelumab therapy, the primary clinical concern is not that avelumab causes Merkel cell carcinoma, but rather that it is used to treat the disease. The evidence indicates that avelumab is an effective treatment for metastatic MCC, with no data suggesting it induces or increases the risk of developing MCC. Instead, the risk narrative centers on the possibility of disease progression or refractoriness to avelumab.

Clinical Outcomes and Management of Avelumab-Refractory Disease

For patients who become refractory to avelumab, alternative treatment options are limited. In Europe, approved systemic therapies for MCC are limited to avelumab (https://pubmed.ncbi.nlm.nih.gov/33439294/). For avelumab-refractory patients, combined ipilimumab plus nivolumab has been investigated. In a retrospective multicenter study of the prospective skin cancer registry ADOREG, patients with avelumab-refractory MCC treated with ipilimumab plus nivolumab showed responses (https://pubmed.ncbi.nlm.nih.gov/36450381/). Similarly, a separate retrospective study reported that ipilimumab plus nivolumab was used in anti-PD-L1/PD-1 refractory MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). In a small case series from three German academic sites, three out of five patients with avelumab-refractory MCC responded to combined ipilimumab plus nivolumab according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). Regarding adverse effects, avelumab, like other checkpoint inhibitors, can cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case described hypercalcemia due to reactivation of sarcoidosis during avelumab treatment for metastatic MCC, which was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case illustrates that while avelumab can trigger immune-mediated adverse events, these are distinct from causing MCC itself.

Causation Analysis: Avelumab Exposure and MCC Development

From a causation-focused clinical interpretation, the timeline between avelumab exposure and health outcomes is relevant. Avelumab is administered to patients already diagnosed with MCC, so the exposure occurs after disease onset. The documented outcomes include objective responses (e.g., tumor shrinkage) in approximately one-third of chemotherapy-refractory patients, as well as potential immune-related adverse events that can occur during treatment. There is no evidence in the provided literature of avelumab causing de novo MCC or increasing the risk of developing MCC. Instead, the risk for affected patients is primarily related to the possibility of not responding to avelumab or experiencing disease progression while on therapy, which occurs in about half of patients. In summary, the medical literature consistently positions avelumab as a therapeutic agent for metastatic MCC, not as a causative factor for the disease. The safety-communication context should emphasize that avelumab is an approved and effective treatment for MCC, with the main risks being lack of response, disease progression, and immune-related adverse events. For patients who are refractory to avelumab, alternative immune checkpoint inhibitor combinations such as ipilimumab plus nivolumab may offer benefit. There is no evidence to support a causal link between avelumab exposure and the development of Merkel cell carcinoma.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, the medical literature does not support that avelumab causes Merkel cell carcinoma. Avelumab is an immune checkpoint inhibitor used to treat metastatic Merkel cell carcinoma. Evidence from clinical trials and studies indicates that avelumab is an effective treatment for MCC, with no data suggesting it induces or increases the risk of developing the disease. The primary risks associated with avelumab are lack of response, disease progression, and immune-related adverse events.

What are the risks of avelumab treatment for Merkel cell carcinoma?

The main risks of avelumab treatment include the possibility of not responding to therapy (approximately one-third of patients achieve objective responses), disease progression while on therapy (about half of patients progress), and immune-related adverse events such as hypercalcemia due to reactivation of sarcoidosis. These risks are distinct from causing MCC itself. For patients who become refractory, alternative treatments like ipilimumab plus nivolumab may be considered.

Does submitting information create an medical context-client relationship?

No. Submission requests an initial records screening only and does not create an medical context-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.